According to the World Health Organization (WHO), 1/3 of world population are carrying Bacillus causing tuberculosis. Every year, about 10 million cases of sick and from 2-3 million people dying from this disease, especially in the developing countries.
Currently there are about 300,000 new tuberculosis cases were resistant to this status and are on the increase. According to the World Health Organization (WHO), 1/3 of world population are carrying Bacillus causing tuberculosis. Every year, about 10 million cases of sick and from 2-3 million people dying from this disease, especially in the developing countries.
Advantages of bedaquilin
Bedaquilin (trade name sirturo) is an anti-tuberculosis drug group diarylquinolin, was discovered by a team of scientists led by Koen Andries headed in the pharmaceutical company Janssen Pharmaceutica. This is the first new tuberculosis medicines research, following testing during the past 40 years since the emergence of drug-resistant tuberculosis rifampine was manufactured in 1963. The special thing is that it is proven to have the ability to treat resistant TB-a littering problem currently when tuberculosis tend to increase with the difficult form of treatment and expensive in terms of money.
Bedaquilin has brought many new promising in fighting tuberculosis-a disease kills more people in the world and only behind the AIDS-after satisfactory results from the experiments on mice. An experiment by the pharmaceutical group Johnson and Johnson made with the participation of research groups in Belgium, France and Sweden. Bedaquilin impact of the ATP synthase molecules are proton pump (this is specialized in molecular synthesis of ATP is the energy for the active bacteria), do disable this molecule. This mechanism is not the same with the smoking group quinolon drug's impact on DNA gyrase (a DNA cutting enzyme is). Also had the smoking group quinolon inhibit the process of Division of TB bacilli was used long ago as levofloxacin or ofloxacin. However, the discovery of bedaquillin is regarded as the hope for resistant tuberculosis patients at present.
According to the research group, this drug has the effect of disabling the enzyme allows substances Bacillus tuberculosis arise active energy needed, at the same time go to the destruction of nature of this enzyme. The scientist Hans Koen Andries said, the new drugs in combination with isoniazide and pyrazinamide antibiotic two kinds will focus in the lungs and the body of infection Mycobacterium tuberculosis to destroy them. This is a different operation mechanism with 3 rows of anti-tuberculosis drugs 1 include rifampine, isoniazide and pyrazinamide, are combined in the treatment of tuberculosis so far. After 1 month of treatment with the antibiotic, treatment time in mouse experiments reduced twice in comparison with current treatment methods. In addition, one template experiments showed bacilli have completely disappeared after 2 months of treatment.
Some note when taking medication
Bedaquilin was first introduced in 2004 at the Scientific Conference on antibiotics and chemotherapy (ICAAC), after a research process that lasted 7 years. One of the first clinical study of bedaquillin is a testing phase II with 47 patients, showed that the drug has the effect of reducing the time from detection to be tuberculosis in sputum sputum no longer transplant to tuberculosis bacilli. A phase II trial was next published in 2010, was funded by Tibotec and the TB Alliance organization. The drug is manufactured by Johnson Johnson (J&J) &, corporations have been approved by the FDA for the drug, a form of temporary approval for these diseases lack of other viable treatment options. By achieving a temporary approval for a drug treatment for a forgotten disease such as tuberculosis, now, J&J can urge the FDA to review drugs in the future to take on the pharmaceutical market as a new achievement in the fight against tuberculosis. The FDA has formally approved this drug for the treatment of tuberculosis as part of the program quick approval apply only with multi drug-resistant tuberculosis.
However, at present, there is still some controversy surrounding the approval of the drug as the FDA's decision was based on an alternate results (implanted phlegm) going backwards with the mortality rate. In the clinical trials advocating approval, patients drink bedaquilin have a higher risk of death even though the results showed tuberculosis bacilli phlegm implantation be resolution. The unwanted effects of the most popular bedaquilin in the study include nausea, muscle pain and headache, chest. Smoking also warned the black box (which is a kind of warning on the packaging of the drugs used as single) demonstrates that the study showed the drug significantly influence risk of serious or even life-threatening, causing cardiac arrhythmia and prolonged QT syndrome caused by hERG channel blockers (a potassium-channel role in the electrical activity of the heart).
No comments:
Post a Comment